Stock 4880 CELLSOURCE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CellSource Co., Ltd.

Equities

4880

JP3423580004

Healthcare Facilities & Services

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
1,522 JPY +0.33% Intraday chart for CellSource Co., Ltd. +3.75% +19.00%
2023 Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI
2023 MEDERI Inc. announced that it has received funding from CellSource Co., Ltd. CI

Valuation

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 15,629 51,949 119,696 82,122 35,225 30,144 - -
Enterprise Value (EV) 1 15,629 50,196 117,288 78,999 30,541 30,144 30,144 30,144
P/E ratio 59.1 x 187 x 183 x 80.6 x 36.5 x 49.9 x 35.4 x 26.8 x
Yield - - - - 1.12% 0.28% 0.35% 0.44%
Capitalization / Revenue 9.7 x 28 x 41 x 19.2 x 7.81 x 6.16 x 5.34 x 4.61 x
EV / Revenue 9.7 x 28 x 41 x 19.2 x 7.81 x 6.16 x 5.34 x 4.61 x
EV / EBITDA - - - 50.3 x - 31.5 x 22.2 x 17.2 x
EV / FCF 107 x 177 x - 121 x 120 x 58 x 31.3 x 25.8 x
FCF Yield 0.93% 0.56% - 0.83% 0.83% 1.72% 3.2% 3.88%
Price to Book 9.72 x 25.6 x 44.4 x 22 x 5.73 x 4.83 x 4.32 x 3.78 x
Nbr of stocks (in thousands) 17,280 18,335 18,586 18,685 19,756 19,806 - -
Reference price 2 904.4 2,833 6,440 4,395 1,783 1,522 1,522 1,522
Announcement Date 12/12/19 12/14/20 12/13/21 12/14/22 12/15/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,611 1,855 2,922 4,274 4,510 4,895 5,648 6,535
EBITDA 1 - - - 1,631 - 956.7 1,357 1,755
EBIT 1 326 415 992 1,571 1,221 841.3 1,206 1,612
Operating Margin 20.24% 22.37% 33.95% 36.76% 27.07% 17.19% 21.35% 24.67%
Earnings before Tax (EBT) 1 303 412 1,006 1,584 1,239 852.7 1,206 1,612
Net income 1 199 274 651 1,018 923 603 849.7 1,124
Net margin 12.35% 14.77% 22.28% 23.82% 20.47% 12.32% 15.04% 17.2%
EPS 2 15.30 15.19 35.17 54.54 48.88 30.50 42.97 56.77
Free Cash Flow 1 146 293 - 678.2 293 519.5 964 1,170
FCF margin 9.06% 15.8% - 15.87% 6.5% 10.61% 17.07% 17.9%
FCF Conversion (EBITDA) - - - 41.57% - 54.3% 71.02% 66.65%
FCF Conversion (Net income) 73.37% 106.93% - 66.63% 31.74% 86.15% 113.46% 104.05%
Dividend per Share 2 - - - - 20.00 4.333 5.333 6.667
Announcement Date 12/12/19 12/14/20 12/13/21 12/14/22 12/15/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: October 2020 S1 2021 S1 2022 Q1 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1
Net sales 1 886 1,343 820 1,697 1,175 1,401 2,577 1,060 1,111 2,171 1,236 1,174 1,121 2,293 1,257 1,382 2,610 1,477 1,582 3,059
EBITDA - - - - - - - - - - - - - - - - - - - -
EBIT 1 187 422 244 490 448 633.1 1,081 351.3 308.1 659.3 384 205.9 195.5 401 259.5 212 580 326 385 710
Operating Margin 21.11% 31.42% 29.76% 28.87% 38.13% 45.19% 41.95% 33.15% 27.73% 30.38% 31.07% 17.54% 17.44% 17.49% 20.64% 15.34% 22.22% 22.07% 24.34% 23.21%
Earnings before Tax (EBT) 1 187 435 244 495 451 637.6 1,089 339.6 319.3 658.8 426 212.7 289 498 209 171 - 326 385 710
Net income 1 118 268 155 308 281 428.8 709.8 216 194 410.1 265 143.9 156.5 297.5 172.5 144.5 370 226 267 493
Net margin 13.32% 19.96% 18.9% 18.15% 23.91% 30.61% 27.55% 20.39% 17.46% 18.89% 21.44% 12.26% 13.96% 12.97% 13.72% 10.46% 14.18% 15.3% 16.88% 16.12%
EPS 6.641 14.55 8.360 16.54 15.04 - - 11.56 10.38 21.94 14.05 7.270 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - -
Announcement Date 6/15/20 6/14/21 3/16/22 6/13/22 9/13/22 12/14/22 12/14/22 3/14/23 6/14/23 6/14/23 9/13/23 3/11/24 - - - - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 1,753 2,408 3,123 4,684 - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 146 293 - 678 293 520 964 1,170
ROE (net income / shareholders' equity) 19.9% 15% 27.5% 31.6% 18.7% 9.77% 12.9% 15%
ROA (Net income/ Total Assets) 23.9% 19.6% 35.2% 25.6% 20.8% 10.7% 12.7% 14.7%
Assets 1 833.8 1,395 1,850 3,983 4,436 5,662 6,717 7,646
Book Value Per Share 2 93.00 111.0 145.0 200.0 311.0 315.0 353.0 403.0
Cash Flow per Share 2 20.20 18.80 38.10 57.80 53.20 36.00 45.00 51.00
Capex 1 49 37 55 99.2 553 50 60 65
Capex / Sales 3.04% 1.99% 1.88% 2.32% 12.26% 1.02% 1.06% 0.99%
Announcement Date 12/12/19 12/14/20 12/13/21 12/14/22 12/15/23 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for CellSource Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
CELLSOURCE CO., LTD. Stock CellSource Co., Ltd.
+19.00% 191M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.89% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.46B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.35% 2.38B
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-15.34% 1.03B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. 4880 Stock
  4. Financials CellSource Co., Ltd.